Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sigyn Therapeutics Inc (OP: SIGY )

0.0700 UNCHANGED
Streaming Delayed Price Updated: 9:58 AM EDT, Jun 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.0700
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0700
Today's Range 0.0700 - 0.0700
52wk Range 0.0900 - 0.4800
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Sigyn Therapeutics Discloses "DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES" Patent Submission and Related ImmunePrepTM Trademark Application
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
Sigyn Therapeutics Reports First Quarter 2023 Financial Results
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire

Performance

YTD
-68.18%
-68.18%
1 Month
-36.94%
-36.94%
3 Month
-78.12%
-78.12%
6 Month
-71.99%
-71.99%
1 Year
-79.62%
-79.62%

More News

Read More
Sigyn Therapeutics Announces Appointment of Annette Marleau, Ph.D. as Chief Scientific Officer
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Sigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-K
Via NewMediaWire
Topics Regulatory Compliance
Exposures Legal Regulatory
Sigyn Therapeutics Announces Third Quarter 2022 Financial Results
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
Sigyn Therapeutics Discloses Trademark Applications to Register ChemoPrepTM and ChemoPureTM for Devices to Enhance Cancer Therapy
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
Sigyn Therapeutics Announces Cancer-Related Patent Submission Entitled: System and Methods to Enhance Chemotherapy Delivery and Reduce Toxicity
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
Sigyn Therapeutics Strengthens Board of Directors With the Appointments of Richa Nand, Jim Dorst and Christopher Wetzel
Via NewMediaWire
Topics Intellectual Property
Exposures Intellectual Property
Sigyn Therapeutics Announces First-In-Human Clinical Strategy to Address Inflammation and Endotoxemia in End-Stage Renal Disease Patients
Via NewMediaWire
Topics Death
Exposures Death
Sigyn Therapeutics Announces Second Quarter 2022 Financial Results
Via NewMediaWire
Sigyn Therapeutics to Commence Trading on the OTCQB Venture Exchange
Via NewMediaWire
Sigyn Therapeutics Appoints Donald J. Hillebrand, M.D. to its Scientific Advisory Board
Via NewMediaWire
Topics Death
Exposures Death
Sigyn Therapeutics Appoints Ajay Verma, M.D., Ph.D. to Its Scientific Advisory Board
Via NewMediaWire
Sigyn Therapeutics Announces Filing of 2021 Annual Report on Form 10-K
Via NewMediaWire
Topics Death
Exposures Death
Sigyn Therapeutics Appoints H. David Humes, MD to Its Scientific Advisory Board
Via NewMediaWire
Sigyn Therapeutics Appoints Alexander S. Yevzlin, MD, FASN to Its Scientific Advisory Board
Via NewMediaWire
Topics Death
Exposures Death
Sigyn Therapeutics Appoints Accomplished Financial Executive, Jeremy Ferrell, as Chief Financial Officer
Via NewMediaWire
Sigyn Therapeutics Announces Completion of Animal Studies
Via NewMediaWire
Sigyn Therapeutics to Present at the Bullseye Small Cap Virtual Investor Conference
Via NewMediaWire
Sigyn Therapeutics Announces Presentation at Today's Emerging Growth Conference
Via NewMediaWire
Sigyn Therapeutics CEO Note: 2021 Milestone Achievements / 2022 Clinical Progression / Images of Sigyn Therapy in Action
Via NewMediaWire
Sigyn Therapeutics CEO Note: As Omicron Surges, Consider That the First Authorized COVID-19 Therapies Were Not Drugs or Vaccines
Via NewMediaWire
Exposures COVID-19
Sigyn Therapeutics Reports the Successful Completion of a Study to Address Gram-Positive Bacterial Toxins Associated with Sepsis
Via NewMediaWire
Topics Death
Exposures Death
Sigyn Therapeutics Featured on National Public Radio: Addressing the Cytokine Storm
Via NewMediaWire
Exposures COVID-19
Sigyn Therapeutics CEO Note: A Treatment Candidate to Address Bloodstream Pathogens, Deadly Toxins and Inflammatory Disease Targets
Via NewMediaWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.